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E-mail: jayden.smith@citc-ltd.co.ukIn response to injuries to the CNS, astrocytes enter a reactive
state known as astrogliosis, which is believed to be deleterious
in some contexts. Activated astrocytes overexpress intermedi-
ate ﬁlaments including glial ﬁbrillary acidic protein (GFAP)
and vimentin (Vim), resulting in entangled cells that inhibit
neurite growth and functional recovery. Reactive astrocytes
also secrete inﬂammatory molecules such as Lipocalin 2
(Lcn2), which perpetuate reactivity and adversely affect other
cells of the CNS. Herein, we report proof-of-concept use of
the packaging RNA (pRNA)-derived three-way junction
(3WJ) motif as a platform for the delivery of siRNAs to down-
regulate such reactivity-associated genes. In vitro, siRNA-3WJs
induced a signiﬁcant knockdown of Gfap, Vim, and Lcn2 in a
model of astroglial activation, with a concomitant reduction
in protein expression. Knockdown of Lcn2 also led to reduced
protein secretion from reactive astroglial cells, signiﬁcantly
impeding the perpetuation of inﬂammation in otherwise quies-
cent astrocytes. Intralesional injection of anti-Lcn2-3WJs in
mice with contusion spinal cord injury led to knockdown of
Lcn2 at mRNA and protein levels in vivo. Our results provide
evidence for siRNA-3WJs as a promising platform for amelio-
rating astroglial reactivity, with signiﬁcant potential for
further functionalization and adaptation for therapeutic appli-
cations in the CNS.
INTRODUCTION
Astrocytes are abundant and highly heterogeneous cells that provide
a variety of essential support and regulatory functions within the
CNS.1,2 In response to CNS pathologies such as spinal cord injury
(SCI), stroke, multiple sclerosis (MS), and Alzheimer’s disease, astro-
cytes show changes in gene expression, cellular structure, and func-
tion. Such responses are commonly referred to as astrogliosis.3–6
Astrocyte reactivity is a ubiquitous response to CNS damage medi-
ated by a complex and insult-speciﬁc mixture of cytokines, factors,
and cellular debris, released by CNS resident damaged cells, inﬂam-
matory inﬁltrates, and even reactive astrocytes themselves, at and
around the site of the insult.7 The pathological role of astrogliosis isMolecular Th
This is an open access article under tcontroversial,8 but is generally considered to be a double-edged
sword, mitigating the acute stresses that develop immediately
following a pathogenic event, but ultimately serving as an impedi-
ment to neural plasticity as the phenomenon persists.9 For example,
the archetypical hallmark of astrogliosis is the overexpression of cyto-
skeletal intermediate ﬁlament (IF) proteins, notably glial ﬁbrillary
acidic protein (GFAP) and vimentin (Vim), contributing to the hy-
pertrophy and entanglement of reactive astrocytes that contribute
to produce a dense barrier serving as the primary basis of the glial
scar.6 This physicochemical barrier provides a protective fortiﬁcation
against the inﬁltration of inﬂammatory agents during the early stages
of a CNS insult, but becomes an obstacle to remyelination, neuronal
regeneration, and overall neural plasticity as the scar persists beyond
the initial effects of the injury. Furthermore, reactive astrocytes play
an important and complex role in modulating neuroinﬂammation,
eliciting a context-dependent array of pro-inﬂammatory or anti-in-
ﬂammatory effects in the CNS via secreted mediators and interactions
with resident immune cells.10 One particularly notable vector is the
secretion of the iron-trafﬁcking protein Lipocalin 2 (Lcn2), which
is canonically associated with innate immune responses but also
described to act as a neuroinﬂammatogen in many CNS pathologies,
including SCI and MS.11,12 Astrocyte-secreted Lcn2 is known
to exacerbate neuroinﬂammation by inducing pro-inﬂammatoryerapy: Nucleic Acids Vol. 10 March 2018 ª 2017 The Authors. 103
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Molecular Therapy: Nucleic Acidspolarization in recipient astrocytes and microglia, even promoting
cell death in neurons.13
Thus, modulation of astrocyte reactivity, or speciﬁc aspects thereof, is
a particularly attractive therapeutic strategy in the treatment of a
diversity of CNS disorders.
One approach that has demonstrated some promising results has
involved interfering with the astrogliotic overexpression of the IF pro-
teins GFAP and Vim, particularly prominent targets in reactive astro-
cytes. In vitro, decreased IF expression has been shown to yield a
concomitant decrease in astrocyte reactivity and hypertrophy, with
co-cultured neurons exhibiting enhanced survivability and increased
neurite growth.14–17 In vivo, IF depletion has been found to result in
decreased scar density, increased axonal plasticity, and improved
functional recovery in mouse models of SCI and other CNS in-
sults.15,16,18–20 These in vivo results have typically been obtained using
constitutive knockout animal models devoid of Gfap and/or Vim.
Such animals have an impaired ability to undergo astrogliosis and
are thus denied the early protective aspects of reactive astrocytes,
making them more susceptible to exacerbating mechanical injury
despite longer-term improvements in axonal outgrowth. Indeed,
the therapeutic utility of the wholesale ablation of astrogliosis is
controversial.8 Perhaps a more promising therapeutic option is the
modulation of injury-aggravating inﬂammation through depletion
of secreted factors, such as Lcn2. Knockout of Lcn2 has been found
to largely negate the pro-inﬂammatory polarization of activated
astrocytes in vitro and in vivo,21,22 yielding better histopathological
outcomes in mouse models of stroke, demyelinating diseases, or
SCI.11,23–25 Lcn2-deﬁcient (Lcn2/) mice display remarkable
neuronal survival and myelin sparing after contusion SCI.11 Impor-
tantly, these changes are accompanied by signiﬁcant reduction of
inﬂammatory responses and improved locomotor recovery.11
Nevertheless, gene knockout is not a clinically viable option, nor is it
necessarily desirable because most genes also serve important physi-
ological functions and their constitutive deletion can have adverse
effects. An ideal therapy would consist of a temporally and dose-
controlled means by which to modulate astroglial reactivities, such
as that afforded by RNAi. Lentiviral delivery of short hairpin RNAs
has been successfully used to reduce astrocyte reactivity
in vitro;14,18 yet there are safety concerns with the therapeutic trans-
lation of viral vectors. As an alternative, small interfering RNA
(siRNA) therapeutics possess great potential for the transient knock-
down of gene expression. In vivo functional recovery in SCI rodents
has been observed using Gfap- and Vim-targeting siRNAs;15,16 how-
ever, the clinical translation of siRNA therapeutics has been
hampered by their relative fragility and inefﬁciency in their delivery.
Nevertheless, the burgeoning ﬁeld of nanotechnology offers hope for
the development of effective, targeted RNA-based therapeutics.
Nanotechnological RNA delivery vehicles encompass a myriad of
chemistries including complexation with carrier polymers, encapsu-
lation within lipid vesicles, or coating onto organic or inorganic nano-
particles. Moreover, due to its ﬂexibility and intrinsic potential for104 Molecular Therapy: Nucleic Acids Vol. 10 March 2018target recognition and enzymatic activity, RNA itself has been em-
ployed as a scaffold from which to develop multifunctional nano-
structures.26–28 Building upon the principles of DNA origami29 and
tecto-RNA,30 a variety of RNA-based nanotriangles,31 cubes,32
rings,33 and lattices34 have been designed as putative therapeutic plat-
forms. Self-assembly of siRNA polymers generated via rolling circle
transcription has even allowed for the generation of RNAi micro-
sponges35 and nanosheets.36
Herein, we describe proof-of-concept evidence of the packaging RNA
(pRNA) three-way junction (3WJ) as a platform for the delivery of
anti-IF or anti-Lcn2 siRNAs to reactive astrocytes in vitro and in vivo.
The pRNA-3WJ, itself a basic unit for the construction of more elab-
orate RNA nanostructures,37 has demonstrated remarkable versatility
as a targeting and therapeutic delivery agent, excelling in the targeted
delivery of anti-miRNAs and siRNAs.38–41 The pRNA platform is
highly stable, non-toxic, biocompatible, and ideally sized for nano-
therapeutic applications,42 with the multi-armed nature of the 3WJ
core allowing for the design of multifunctional, modular con-
structs.43,44 This technology has seen extensive use in anti-cancer or
anti-viral roles, but here we report the ﬁrst progress toward applica-
tions in the CNS niche.
RESULTS
Astrocytes Cultured in Low-FBS Medium Enter a Reactive State
When Exposed to Lipopolysaccharide + Interferon-g
Differentiation of neural stem cells (NSCs) into astrocytes was
induced by the presence of fetal bovine serum (FBS), a well-estab-
lished technique,45–47 with 15 days in vitro (DIV) chosen as a time
point at which cultured astroglial cells had achieved a desirable level
of maturity.47 Immunoﬂuorescence imaging revealed uniform
expression of GFAP and Vim, and high expression of the astroglial
markers S100 calcium-binding protein B (S100B)48 and 10-formylte-
trahydrofolate dehydrogenase (Aldh1l1)49 (Figure S1). We employed
a two-phase differentiation protocol, switching from high-FBS (10%)
to low-FBS (1%) N2-supplemented medium at 7 DIV to minimize the
intrinsic astroglial reactivity attributable to the described stimulatory
effect of serum.35,36 Differentiation medium was supplemented with
FGF2 to further promote a mature, resting-like phenotype.50 By
contrast to the hypertrophic, polygonal astrocyte clusters derived
via the high-FBS technique, low-FBS astrocytes were conﬂuent and
ramiﬁed with long processes (Figure S1). These morphological differ-
ences, coupled with the signiﬁcantly less intense GFAP and Vim
expression observed in low-FBS astrocytes, suggested a strong basal
reactivity in high-FBS astrocytes.
In order to have a simple and reproducible in vitromodel of astroglio-
sis, we activated astrocytes through exposure to lipopolysaccharide
(LPS) and interferon-g (IFN-g).51 Our reﬁned activation protocol
involved exposure to LPS+IFN-g for 48 hr at 15–17 DIV, with
RNA analyses at 17 DIV and protein analyses at 20 DIV.
Low-FBS astrocytes treated with LPS+IFN-g for 48 hr exhibited
an upregulation of Toll-like receptor 4 (Tlr4) and IFN-g receptors
Figure 1. Response of Low-FBS/+FGF2 Cultured Astrocytes to LPS+IFN-g Stimulation at the mRNA Level
qRT-PCR quantification of relative mRNA expression levels of Ifngr1, Ifngr2, Ciita, Tlr4, Gfap, Vim, Lcn2, Nos2, Tnf, Il1b, and Il6. Expression relative to resting controls
(2DDCt method),Gapdh reference gene. Data expressed as the mean of nR 3 biological replicates ± SD; *p% 0.05, **p% 0.01, ***p% 0.001; or ****p% 0.0001, relative to
non-activated control samples (one-way ANOVA with Dunnett’s multiple comparison test).
www.moleculartherapy.org1 and 2 (Ifngr1/Ifngr2). After a subsequent 48 hr in LPS+IFN-g-free
medium, expression of the above mRNAs reverted to basal levels.
Likewise, major histocompatibility complex class II transactivator
(Ciita) was induced in the 48 hr following activation and persisted
elevated at 96 hr (Figure 1). We also observed an increased expression
of both Gfap and Vim at 48 hr post-treatment. However, the induc-
tion of Gfap failed to achieve statistical signiﬁcance. Instead,
Lcn2 expression underwent a 15,000-fold induction upon 48-hr
LPS+IFN-g treatment, dropping off signiﬁcantly after a further
48 hr in LPS+IFN-g-free medium. Other accepted pro-inﬂammatory
genes were upregulated after LPS+IFN-g, including interleukin-6
(Il6), tumor necrosis factor (Tnf), and nitric oxide synthase 2
(Nos2). The expression of these activation genes also reverted toward
resting levels upon withdrawal of the LPS+IFN-g medium.
Conversely, the expression of the pro-inﬂammatory cytokine Il1b
was signiﬁcantly downregulated by LPS+IFN-g (Figure 1).We also examined the effects of the activation of low-FBS astrocytes
at protein level, most fundamentally by an increase in pSTAT3 (Fig-
ure 2A). The kinetics of this induction were quite rapid, with pSTAT3
showing a peak in expression at 1 hr and subsequent decrease by
48 hr. At a more general level, activated astrocytes also exhibited
increased early expression of Lcn2 (Figure 2B), as well as the IF pro-
teins GFAP and Vim (Figure 2C), most evident at 3 days post-activa-
tion. In immunoﬂuorescence assays, Lcn2 exhibited a remarkable
upregulation, from no obvious expression in resting-like conditions
up to an intense expression in most cells upon activation (Figure 2D).
This activation response was further reﬂected by an approximately
50-fold increase in IL-6 secretion at 48 hr after LPS+IFN-g
(Figure 2E).
On the other hand, high-FBS astrocytes showed a constitutive high
reactivity, evident from signiﬁcantly higher basal expression ofMolecular Therapy: Nucleic Acids Vol. 10 March 2018 105
Figure 2. Response of Low-FBS/+FGF2 Cultured
Astrocytes to LPS+IFN-g Stimulation at the Protein
Level
(A) Representative western blot illustrating temporal in-
duction of pSTAT3 upon 1 and 48 hr of treatment with
LPS+IFN-g. (B and C) Representative western blots of
activation markers in resting versus LPS+IFN-g-stimu-
lated low-FBS astrocytes: (B) Lcn2 expression in resting
and 24-hr-stimulated astrocytes; and (C) GFAP and Vim
levels under resting conditions and following 48 hr of
activation followed by 3 or 5 days of rest. b-Actin was used
as a loading control. (D) Representative immunofluores-
cence micrographs of GFAP, Vim, and Lcn2 immunore-
activity in resting and activated conditions (GFAP/Vim:
green; Lcn2: red; DAPI nuclear stain: blue). Scale bars,
100 mm. (E) Secreted IL-6 as measured by ELISA, resting
versus activated conditions, at 48 and 120 hr post-stim-
ulation. Data are expressed as the mean of n R 3
biological replicates ± SD. *p % 0.05, relative to non-
activated control samples (multiple t tests with statistical
significance determined using the Holm-Sidak method,
a = 0.05).
Molecular Therapy: Nucleic AcidsVim, GFAP, and Lcn2, as compared with resting-like low-FBS as-
trocytes. Moreover, ostensibly resting-like high-FBS astrocytes were
seen to have a strong pSTAT3 expression. High-FBS astrocytes
treated with LPS+IFN-g for 48 hr exhibited signiﬁcant inductions
in Nos2 and Il6, as well as increased secretion of IL-6. However,
Tnf expression showed no change, nor did Gfap and Vim. An
induction of Lcn2 was evident upon LPS+IFN-g treatment. Il1b
also remained unchanged upon activation; however, levels in the
high-FBS astrocytes were signiﬁcantly lower than low-FBS analogs
(Figure S2).
These ﬁndings supported the use of low-FBS astrocytes for the exper-
iments described hereafter.
siRNA-3WJ Nanostructures Have Negligible Toxic Effects upon
Transfection into Astrocytes
siRNA-3WJs of the general scheme depicted in Figure 3A were pre-
pared based on the methods described previously.43 The siRNA-
3WJs used herein were named according to their target mRNA and106 Molecular Therapy: Nucleic Acids Vol. 10 March 2018the identiﬁcation number of each given
SMARTpool siRNA analog (Table S1), thus
giving rise to G10-3WJ (anti-GFAP), V10-3WJ
(anti-Vim), L12-3WJ (anti-Lcn2), and the non-
targeted N03-3WJ (as negative control). The
three component strands of each siRNA-3WJ
were mixed in stoichiometric ratio and annealed
to generate the 3WJ nanoparticle. Successful as-
sembly of the siRNA-3WJs was conﬁrmed by
the decreased gel mobility of the multistranded
structures in electrophoretic assays relative to
single- and double-component constructs (Fig-
ure 3B), with dynamic light scattering measure-ments sizing the siRNA-functionalized L12- and N03-3WJs at 5.12 ±
1.13 and 4.83 ± 1.38 nm, respectively (Figure 3C).
Once assembled, siRNA-3WJs were delivered to astrocytes in vitro by
means of lipofection. Unless otherwise noted, transfections occurred
at 15 DIV with subsequent evaluation of mRNA levels via qPCR at 17
DIV and proteins via western blot or ﬂuorescence microscopy at 20
DIV. Transfections were performed in three different activation con-
texts: a resting proﬁle in which astrocytes were not treated with LPS+
IFN-g, and two different activation proﬁles wherein LPS+IFN-g treat-
ment occurs either in the 48 hr prior to transfection (i.e., 13–15DIV) or
the 48 hr commencing with transfection (i.e., 15–17 DIV) (Figure 3D).
The former activation proﬁle, henceforth referred to as a therapeutic
intervention, simulates the treatment of an established CNS insult,
whereas the latter proﬁle, a preventative intervention, explores the utility
of these putative nanotherapeutics in inhibiting a reactive response.
Transfection efﬁciency of siRNA-3WJs under these various activation
conditions was assessed using Cy3-labeled N03-3WJ (Cy3_N03-3WJ)
Figure 3. Synthesis, Delivery, and Safety of siRNA-3WJ Nanostructures
(A) Generic 3WJ scheme depicting the three constituent RNA strands, variable siRNA (N) and 3WJ core moieties (black circles indicate a wobble base pair). (B) Agarose gel
(2%, TBM buffer) illustrating the characterization of 3WJ assembly by gel mobility. The assembled 3WJs show retarded mobility relative to a double-stranded (A+C strands)
construct or single A orB strands alone. An Ultra-Low Rage dsDNA ladder is used as reference. (C) Dynamic light scattering (DLS) size characterization of representative L12-
and N03-3WJs. Results are expressed asmean hydrodynamic size (nm)±SD. (D) Differentiation/treatment scheme: NSCs are differentiated in amedium containing high FBS
(legend continued on next page)
www.moleculartherapy.org
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Molecular Therapy: Nucleic Acidsat a 20 nM concentration. As early as 24 hr post-transfection cells
were ﬁxed and processed for immunoﬂuorescence, with the fraction
of transfected astrocytes estimated by co-localization of punctuate
Cy3 staining with GFAP-immunoreactive cells (over total nuclei).
Transfection efﬁciencies, ascertained as the fraction of Cy3+ cells,
were always found to be >70% under resting, therapeutic, and preven-
tative conditions (Figure 3E). No uptake was evident without lipo-
fection. Effective internalization of siRNA-3WJs was conﬁrmed
by confocal microscopy, with cross-sectional z stack images of
Cy3_N03-3WJ transfected low-FBS astrocytes showing the presence
of Cy3+ aggregates within the cell bodies (Figures 3F and 3G).
Transfection of astrocytes with these siRNA-3WJ constructs proved
to be non-toxic over the range of concentrations tested. Using color-
imetric LDH cytotoxicity assays, we found that the viability of cells
remained >95% for all siRNA-3WJs (N03-, G10-, V10-, and L12-)
and concentrations tested, thus demonstrating no signiﬁcant cytotox-
icity relative to untreated controls or cells treated with vehicle only.
No toxicity was observed at 24 hr post-transfection, when astrocytes
remained in serum-free transfection media, or as late as 120 hr after
transfection (Figure S3). Furthermore, we checked the stability of
several common reference genes, including glyceraldehyde-3-phos-
phate dehydrogenase (Gapdh), 18S ribosomal RNA (Rna18s5), and
beta-actin (Actb), via TaqMan gene expression assays to establish
their suitability in subsequent qPCR assays. The expression of each
of these putative reference genes at 48 hr post-transfection showed
no variation across treatment or condition (Figure S4).
The potential immunogenicity of the siRNA-3WJs was tested with
respect to their ability to induce the expression of pro-inﬂammatory
cytokine genes in astrocytes. Preliminary assays utilized 3WJs assem-
bled from in vitro transcribed A and C strand single-stranded RNAs
(ssRNAs) that had not been subjected to de-phosphorylation and thus
still possessed 50-triphosphate transcription artifacts. Transfections
with 50-triphosphate N03-, G10-, and V10-3WJs (5 nM) were found
to cause signiﬁcant inductions in Il6 (50-fold), Tnf (400-fold), and
IFN beta 1 (Ifnb1, 100-fold) relative to non-transfected controls
(Figure 3H). Because neither mock-transfected samples nor those
treated with commercial siRNA pools (chemically synthesized and
with proprietary modiﬁcation) had such an effect, we hypothesized
this unwanted exacerbation of the pro-inﬂammatory response to be
the result of retinoic acid-induced gene 1 (RIG-I)-mediated antiviral
immunity,52 triggered by the 50-triphosphate transcription artifacts.for 7 days (red) before being swapped to a low-FBSmedium supplemented with N2 (gre
with 3WJs at day 15 (D15), with RNA and protein expressions were assayed at days 1
through the addition of LPS+IFN-g to the medium for 48 hr: from D13 through D15 for
(E) Immunofluorescence quantification of percentage of astrocytes transfected with 20
mean ± SD; n = 3 biological replicates, 3 coverslips per condition for each experimen
between conditions. (F) z stack confocal micrograph of astrocytes transfected with 20 n
(green), with nuclei co-stained with DAPI (blue). (G) Volocity-based 3D reconstruction (
z stack in (F). (H) Expression of pro-inflammatory cytokines (Ifnb1, Tnf, and Il6) in high-FB
or without [PPP] 50-triphosphate in vitro transcription artifacts) or analogous comme
respectively). Results expressed as the mean mRNA expression (qPCR) relative to non-
reference gene. *p% 0.05; **p% 0.01; ***p% 0.001; or ****p% 0.0001, relative to co
108 Molecular Therapy: Nucleic Acids Vol. 10 March 2018Indeed, introduction of an RNA dephosphorylation step into the
3WJ synthesis completely abolished the induction of IL-6 and
TNF-a, at both mRNA (Figure 3H) and protein levels (Figure S3).
Thus, appropriately modiﬁed 3WJs were found to be non-
immunogenic.
siRNA-3WJ Nanostructures Efficiently Downregulate the
Expression of Reactive Astrocyte-Associated Genes In Vitro
Preliminary assays in high-FBS astrocytes revealed a dose-dependent
silencing response by G10- or V10-3WJs. By qPCR assays, knock-
down of target genes was found to be >50% at 5 nM relative to con-
trols, with no appreciable off-target silencing effects (Figure S5).
Commercial siRNA pools containing multiple chemically modiﬁed
siRNAs against the target gene yielded results comparable with the
analogous unmodiﬁed siRNA-3WJs bearing a single siRNA against
the same target (Figure S5). Higher concentrations (i.e., 50 nM) re-
vealed no further increase in efﬁcacy (data not shown).
Having established 5 nM of either IF-targeted siRNA-3WJ as being
sufﬁcient to induce a signiﬁcant reduction in each respective
mRNA, this concentration was used in subsequent experiments to
further examine the utility of the treatments under activation condi-
tions, as well as to investigate siRNA-3WJ-mediated Lcn2 knockdown.
In low-FBS astrocytes, we achieved signiﬁcant reductions of Gfap and
Vim levels by G10- and V10-3WJs, both in resting and LPS+IFN-g-
activated cells, under therapeutic and preventative settings. In both
resting and activation conditions, G10-3WJ decreased Gfap expres-
sion by >60% (Figure 4A). V10-3WJs yielded similar results, with
Vim expression knocked down by >65% (Figure 4A). No appreciable
synergistic effects were evident in combinatorial treatments
comprising both G10 and V10 simultaneously (Figure 4A).
Knockdown of Lcn2 by L12-3WJs was consistent with the absolute
expression levels of Lcn2 in resting versus activated astrocytes, with
the most signiﬁcant knockdown (87.1% ± 3.7%) being observed in
the resting condition (Figure 4A). L12-3WJ treatments in therapeutic
and preventative conditions exhibited somewhat lower knockdowns
relative to their non-treated controls (81.1% ± 5.4% and 59.2% ±
9.8%, respectively) (Figure 4A). 20-Fluoro-modiﬁed L12-3WJ,
intended for in vivo use due to the higher nuclease resistance of the
20F modiﬁcation,53 demonstrated a comparable knockdown efﬁcacyen) to obtain cells with a mature, resting astrocyte phenotype. Cells were transfected
7 and 20, respectively, unless otherwise noted. Activation of astrocytes is achieved
the therapeutic treatment profile, and from D15 to D17 for the preventative profile.
nM Cy3_N03-3WJ under resting and activated conditions. Data are expressed as
t, and 10 images per coverslip. No statistically significant difference was observed
M Cy3_N03-3WJ (red), fixed 24 hr after transfection, and immunostained for GFAP
from a total of n = 22 z stacks of optical slices in 0.25-mm intervals) of the confocal
S/FGF2-free cultured “resting” astrocytes when transfected with 3WJs (with [+PPP]
rcial siRNA pools (NsiR, GsiR, or VsiR, being non-targeted, anti-Gfap, or anti-Vim,
transfected controls (2DDCt method) with nR 3 biological replicates ± SD; Gapdh
ntrol samples (one-way ANOVA with Dunnett’s multiple comparison test).
Figure 4. siRNA-3WJ Nanotherapeutics Specifically
and Significantly Knock Down Expression of Target
Genes
(A) qPCR assays showing the knockdown of Gfap, Vim,
and Lcn2 target mRNA by 5 nM doses of their respective
siRNA-3WJ nanostructures. Downregulation measured
48 hr after transfection, under resting conditions. Mock
(Lipofectamine-only) or non-targeted negative control
3WJs were used as negative controls. Gapdh was the
reference gene. (B) Densitometric quantification of Vim
(54 kDa) and GFAP (50 kDa) western blots showing
siRNA-3WJ-induced protein knockdown in preventative
activation conditions (20 DIV) and a representative
image. Quantification is expressed relative to b-actin
and normalized to non-transfected control samples.
(C) Representative immunofluorescence micrographs
depicting the decrease in GFAP and Vim immunoreactivity
upon G10- or V10-3WJ treatment, respectively, in pre-
ventative activation conditions, compared with non-
treated and N03-3WJ-treated controls (GFAP and Vim:
green, DAPI-stained nuclei: blue). (D) Quantification and
representative image of Lcn2 (23 kDa) western blot under
resting, therapeutic, and preventative activation condi-
tions upon L12-3WJ treatment (16 DIV), compared with
non-treated controls. Quantification as per (B). (E) Lcn2
immunofluorescence, as per (C), with quantification of
intensity density (n = 3 biological replicates, 2 coverslips
per replicate, 10 fields of view per coverslip) of L12- and
N03-3WJ-treated samples versus non-treated controls
(Lcn2: red; DAPI-stained nuclei: blue). Scale bars,
100 mm. (F) Schematic of the LGV1-3WJ, a single 3WJ
core functionalized with the siRNA moieties of each of the
L12-, G10-, and V10-3WJs. In vitro transcribed RNA
strands LGVa, LGVb, and LGVc are annealed together;
black circles indicate a wobble base pair. (G) Agarose gel
(3%, TBM buffer) illustrating the stepwise assembly and
retarded mobility of the extended LGV1-3WJ construct
relative to single- and double-stranded intermediates.
Ultra-low dsDNA ladder is for reference. (H) qPCR assays
showing the knockdown of Gfap, Vim, and Lcn2 target
mRNA by a 5 nM dose of the LGV1-3WJ nanostructure,
as per the single-siRNA 3WJs in (A). Quantitative results
expressed as the mean of n R 3 biological replicates ±
SD. *p % 0.05; **p % 0.01; ***p % 0.001; or
****p % 0.0001, relative to control samples of the same
activation condition (two-way ANOVA [qPCR] or one-way
ANOVA [western blot] with Dunnett’s multiple comparison
test).
www.moleculartherapy.orgversus the 20-OH form (63.7% ± 4.9%) (Figure S6). LGV1-3WJ,
bearing all three of the siRNA moieties possessed by the L12-,
G10-, and V10-3WJs, produced signiﬁcant downregulation of each
of the three target mRNAs simultaneously at a 5 nM dose under
preventative conditions (Figures 4F–4H).
No signiﬁcant off-target effects were ever observed for targeted 3WJs,
nor did the non-targeted N03-3WJ induce any signiﬁcant change inthe expression of Gfap, Vim, or Lcn2 (Figure 4A). Gfap-, Vim-, or
Lcn2-targeted 3WJs failed to affect the expression of pro-inﬂamma-
tory cytokine genes that included Il6, Nos2, Tnf, and Il1b (Figure S7).
In activated astrocytes, both G10- and V10-3WJs induced signiﬁcant
reductions in GFAP and Vim protein expression, respectively (Fig-
ures 4B and 4C). GFAP levels were decreased 70.3% ± 7.0% by
G10-3WJ treatment, whereas Vim was down 95.0% ± 1.7% uponMolecular Therapy: Nucleic Acids Vol. 10 March 2018 109
Figure 5. L12-3WJ Treatment Ameliorates the
Propagation of Classical Activation by Reactive
Astrocytes
(A) Schematic of the conditioned media transfer experi-
ment. (B) ELISA quantification of Lcn2 in the supernatant
media of resting or LPS+IFN-g-stimulated astrocytes, as
well as activated astrocytes treated with mock, N03, or
L12 transfections, 48 hr after treatment. Asterisk (*) de-
notes statistical significance relative to the supernatant of
non-transfected, activated astrocytes; number sign (#)
is relative to non-transfected, resting astrocytes.
##p % 0.01, ###p % 0.001 relative to resting medium,
***p % 0.001 relative to activated medium. (C–F) qPCR
quantification of activation-associated genes in recipient
cells 24 hr after transfer of media from treated astrocytes:
(C) Gfap, (D) Vim, (E) Nos2, and (F) Lcn2; results are
expressed as themeanmRNA expression relative to those
cells receiving conditioned media from activated controls
(2DDCt method) (Gapdh reference gene). Data represent
the mean of nR 3 biological replicates ± SD. *p% 0.05;
**p % 0.01; ***p % 0.001; or ****p % 0.0001, relative to
control samples in the same activation condition (two-way
ANOVA with Dunnett’s multiple comparison test).
Molecular Therapy: Nucleic AcidsV10-3WJ treatment, both in the preventative setting. Combined treat-
ments invoked comparable downregulation in protein expression for
both IFs, ruling out synergistic effects. A further qualitative assess-
ment of GFAP or Vim expression by immunoﬂuorescence conﬁrmed
the results of the western blots (Figure 4C).
Lcn2 was detected in activated astrocytes by western blot at both 16
DIV (therapeutic and preventative) and 17 DIV (preventative only)
(Figure 4D). Treatment with L12-3WJ yielded a signiﬁcant reduction
of Lcn2 in each condition (Figure 4D): 83.6% ± 5.1% reduction for the
therapeutic setting and 61.2% ± 2.4% for the preventative. This strik-
ing reduction in Lcn2 expression was also evident by immunoﬂuores-
cence, with therapeutic and preventative samples exhibiting Lcn2
immunoﬂuorescence reductions of 67.4% ± 7.0% and 57.8% ±
5.0%, respectively (Figure 4E).
Thus, siRNA-3WJs nanostructures can efﬁciently downregulate the
expression of reactive astrocyte-associated mRNAs and proteins.
siRNA-3WJ Nanostructures Downregulate Lcn2 in Reactive
Astrocytes In Vitro to Inhibit the Propagation of Astroglial
Responses
Secretion of Lcn2 signiﬁcantly increased in activated astrocytes. Re-
placing cell media with fresh DMEM 24 hr after activation and sub-
sequently conditioning that DMEM for an additional 24 hr yielded
secreted Lcn2 concentrations of 0.2 ± 0.1 ng/mL in resting astrocytes
and 21.0 ± 3.2 ng/mL in activated astrocytes (Figure 5B). Concurrent
treatment of activated astrocytes with L12-3WJ reduced the mean110 Molecular Therapy: Nucleic Acids Vol. 10 March 2018secreted Lcn2 concentration to 6.8 ± 1.3 ng/mL, whereas mock or
N03-3WJ treatments had no effect.
To investigate the capacity of siRNA-3WJ nanostructures to inhibit
the propagation of astroglial responses, we assessed the effects of
activated astrocyte-conditioned media (aACM) on resting (sec-
ond-generation) astrocytes (as per the scheme in Figure 5A). Gfap
(Figure 5C) and Vim (Figure 5D) expression levels were unchanged
by aACM, with no appreciable induction between astrocytes treated
with aACM and control ACM. Conversely, we observed a signiﬁ-
cant increase in the expression of Nos2 (Figure 5E) and Lcn2
(Figure 5F) in astrocytes receiving aACM (2.1-fold and 5.9-fold,
respectively). Interestingly, treatment of ﬁrst-generation astrocytes
with L12-3WJ signiﬁcantly reduced the induction of both Nos2
and Lcn2 in aACM-treated second-generation astrocytes (Figures
5E and 5F). Lcn2 also appeared downregulated, albeit much less
signiﬁcantly, by treatment with the ACM from those astrocytes
mock-transfected or transfected with the non-targeted control
N03-3WJ (Figure 5F).
siRNA-3WJ Nanostructures Downregulate Lcn2 In Vivo in an
Experimental Model of Moderate Contusive SCI
To determine the efﬁcacy of L12-3WJ administration in vivo, we em-
ployed an experimental model of moderate contusive SCI. It has been
observed, both in our own studies (data not shown) and in the liter-
ature,11 that Lcn2 expression is signiﬁcantly upregulated at the
mRNA and protein levels starting 1 day postinjury, mainly in
activated astrocytes and inﬁltrating leukocytes. After performing
Figure 6. 20F-L12-3WJ Injection in an Experimental Model of Moderate Contusive Spinal Cord Injury Reduces Lcn2 mRNA and Protein Levels
(A) Schematic representation of 20F-L12-3WJ injection in an experimental model of moderate contusive spinal cord injury. (B) qPCR quantification showing the knockdown of
Lcn2 in mice treated with 10 mg of 20F-L12-3WJ, compared with injury-only control mice (sham), Lipofectamine-only treated mice, 10 mg of 20F-N03-3WJ, and 1 mg of
20F-L12-3WJ-treated mice (n = 3–4 mice per group). **p% 0.01, relative to sham control mice (one-way ANOVA with Dunnett’s multiple comparison test). Data represent
mean ± SD. (C) Quantification of Lcn2-postive volumes in injury-only control mice (sham) versus 10 mg of 20F-L12-3WJ-treated mice. Data are expressed as % of Lcn2+
volume ± SD over the total volume (n = 4 mice per group). *p% 0.05 (Student’s t test). Representative Lcn2 immunohistochemistry images in injury-only control (sham) and
10 mg of 20F-L12-3WJ-treated mice, counterstained with hematoxylin. Original magnification 4; scale bar, 500 mm. Corresponding representative 3D reconstructions
depict the lesion volume in red, with blue contours representing Lcn2+ volumes and light gray contour representing the spinal cord.
www.moleculartherapy.orgmoderate injury, 20F-L12-3WJs or control 3WJs were injected into the
lesion epicenter and mice were sacriﬁced after 2 days (Figure 6A).
These preliminary in vivo data showed a signiﬁcant reduction
(55.7% ± 9.8%) of Lcn2 mRNA in SCI mice treated with a 10 mg
dose of 20F-L12-3WJ, compared with SCI mice injected with control
treatments, whereas SCImice treated with a 1 mg dose of 20F-L12-3WJ
showed little reduction in mRNA expression (Figure 6B). Signiﬁcant
Lcn2 reduction in 20F-L12-3WJ-treated mice was observed at the pro-
tein level via immunohistochemical staining, with quantiﬁcation of
Lcn2+ volumes in these treated mice showing an approximately
55% reduction in Lcn2 expression compared with sham-treated con-
trol SCI mice (Figure 6C).These preliminary in vivo data indicate that the local delivery of
L12-3WJ can efﬁciently downregulate the expression of our gene of
interest at both mRNA and protein levels.
DISCUSSION
Astrocytes are a heterogeneous population of cells, which play signif-
icant roles in a multitude of functions integral to the maintenance of
CNS homeostasis. In response to a diversity of diseases or injuries,
astrocytes enter a reactive state marked by changes in gene expres-
sion, function, andmorphology.3,4,54 This phenomenon, known as as-
trogliosis, is a complex and heterogeneous response to molecular
stimuli that falls on a continuum of severity depending on the context,Molecular Therapy: Nucleic Acids Vol. 10 March 2018 111
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trocytes exhibit varying degrees of reactivity in the normal physiolog-
ical function of the CNS, evincing the non-binary nature of activation.
A canonical manifestation of astrogliosis is the overexpression of IF
proteins such as GFAP and Vim, with subsequent hypertrophy
and entanglement of reactive astrocytes. In severe cases, astrocytes
become proliferative and, in a complex interplay between multiple
cell types and the extracellular matrix, form a dense glial scar.
Several in vitro and in vivo studies of reactive astrocytes show modu-
lation of a plethora of different structural and functional molecules in
an insult-speciﬁc and temporally dependent manner. This diversity is
reﬂected in the proﬁle of effector molecules secreted by reactive astro-
cytes, pro-inﬂammatory and anti-inﬂammatory cytokines, growth
factors, and inhibitory agents, and thus the inﬂuence of such astro-
cytes on their environment. Consequently, astrogliosis is seen as a
double-edged sword in the context of CNS afﬂictions such as SCI,
where reactive astrocytes can play both beneﬁcial and detrimental
roles. Thus, from a therapeutic perspective, gene knockout ap-
proaches toward ablating astrogliosis are undesirable because they
also inhibit the beneﬁcial aspects of acute astrocyte reactivity and
other likely physiological roles for the gene of interest, in addition
to being clinically infeasible. A more translational approach could
be a controlled temporal regulation of astrogliosis, focusing on chron-
ically or excessively reactive astrocytes and/or speciﬁc deleterious
aspects of astrogliosis, rather than complete suppression of the
response.
Lcn2 is emerging as one such promising therapeutic target because of
its signiﬁcant role in astrogliosis and neuroinﬂammation.13 Osten-
sibly involved in iron regulation and the innate immune response,
Lcn2 is upregulated/secreted by reactive astrocytes21,22,56–59 and has
been implicated in the modulation of inﬂammation in a number of
CNS disorders, including SCI,11 MS,25,60–62 and Parkinson’s disease.63
Autocrine/paracrine exposure to Lcn2 has been found to induce po-
larization toward a classically pro-inﬂammatory reactive phenotype
in both astrocytes and macrophages, with typical GFAP upregulation
and morphological changes in the former case, as well as sensitizing
astrocytes and neurons to cytotoxicity.22,57–59,64 Knockout of astro-
cytic Lcn2 has been shown to ameliorate reactivity under in vitro
and in vivo conditions in mouse neuroinﬂammation models,
with Lcn2 deﬁciency found to attenuate the neurotoxic effects of
LPS+IFN-g treatment, inhibiting the overexpression of GFAP and
pro-inﬂammatory markers.11,21,24 Moreover, Lcn2 knockout mice
have exhibited improved neuronal and tissue survival, greater sparing
of myelin, and signiﬁcantly better locomotor recovery than wild-type
mice following contusion SCI.11
Nevertheless, as with the IF proteins, knockout of the gene is not yet a
clinically viable approach due to practical limitations and potential
unintended effects (e.g., Lcn2 is believed to play roles in cognitive
behavior and neurogenesis,12,65 whereas, more broadly, inﬂammatory
processes can convey some degree of neuroprotection under the right
circumstances66).112 Molecular Therapy: Nucleic Acids Vol. 10 March 2018Viral vectors are powerful tools for use in gene therapy applications
and are regularly exploited for transient gene regulation via the deliv-
ery of RNAi agents. However, clinical translation of such systems is
often hindered by several signiﬁcant limitations, including the poten-
tial for immunogenicity or mutagenesis, or difﬁculties in production
and scalability.67 An easily synthesized, modular, dosable, and non-
toxic/non-immunogenic RNAi delivery platform, more reminiscent
of a conventional pharmaceutical drug, has potentially lower hurdles
to surmount on the path to clinical translation. Toward such a goal,
we undertook proof-of-concept experiments to investigate the utility
of pRNA-derived siRNA-3WJ nanotherapeutics in the CNS niche via
downregulation of reactive astrocyte-associated genes (Gfap, Vim,
and Lcn2) in an in vitro model of astrogliosis.
In establishing this model, we employed a convenient system by
which to readily obtain activation-inducible astrocytes through the
differentiation of NSCs45 in low-FBS, FGF2-supplemented media.
The self-renewability of NSCs coupled with the ease of differentiation
made this a more efﬁcient option than harvesting primary astrocytes
and provided a more homogeneous culture. Low FBS proved integral
to obtaining conﬂuent, basally resting astrocytes. We found the high-
FBS (FGF2-free) cultured astrocytes to have a high basal expression of
pro-inﬂammatory markers, IFs, and the activation marker pSTAT3.
Such astrocytes were largely immune to subsequent canonical activa-
tion. Serum is known to invoke a reactive state in astrocytes,68–70 and
FGF signaling has been found to suppress astrocyte activation71,72
and generate a mature, quiescent phenotype with low GFAP expres-
sion in the astroglial differentiation of stem cells.50 Serum restriction
and FGF2 supplementation resulted in more conﬂuent cultures with a
less-reactive morphology and phenotype, and a susceptibility to an
inducible activation response.
Upon LPS+IFN-g exposure, low-FBS cultured astrocytes showed ev-
idence of both a classical pro-inﬂammatory response and canonical
astrocyte reactivity. Increases in the mRNA expression levels of
Tlr4 and Ifngr1/2 in the 48 hr following stimulation demonstrate
the reactivity of these astrocytes to this activation protocol, with
inductions in receptor expression in response to activation being
previously reported in astrocytes for both Tlr473–75 and Ifngr.76
Responsiveness to LPS+IFN-g treatment was further evidenced by
an increase in Ciita, a transcriptional co-activator of the major histo-
compatibility complex (MHC) class II, indicative of the acquisition of
a non-professional antigen-presenting cell functionality in response
to adaptive immune stimuli.77–80 Furthermore, there was a signiﬁcant
induction in Nos2 upon stimulation, an important indicator of
activation and a precursor to the upregulation of IFs.78,81,82 This
pro-inﬂammatory activation response was further evident here as a
signiﬁcant induction in the expression of Il6 in LPS+IFN-g-treated
astrocytes. Absolute mRNA quantities of Il6 and other examined
cytokines were low (and thus inherently noisy) at 48 hr, possibly
due to peak induction having occurred within 24 hr of activation83
and potentially masking relative changes in expression. Nevertheless,
ELISA measurements performed on the supernatant of astrocytes
activated for 48 hr did show a signiﬁcant increase in the concentration
www.moleculartherapy.orgof secreted IL-6. A transient LPS+IFN-g-induced activation
was observed by pSTAT3 western blots, peaking after just 1 hr of
LPS+IFN-g exposure. Lcn2, also regulated via STAT3 activation,
was very signiﬁcantly upregulated relatively quickly in LPS+IFN-g-
treated astrocytes. Intriguingly, Il1b mRNA levels were observed to
decrease substantially upon LPS+IFN-g stimulation despite IL-1b up-
regulation being commonly associated with reactive astrocytes. This
might be attributable to an inhibitory effect of IFN-g on IL-1b pro-
duction that has previously been reported in mouse (but not human)
astrocytes.84 This is supported by in vivo evidence that shows no
IL-1 (a or b) induction in rat astrocytes upon intra-hippocampal
LPS+IFN-g injection.85 Similarly, the very low levels of IL-1b in
high-FBS culture astrocytes might be because of their high basal
expression of IL-6, which can also reportedly inhibit IL-1b
expression.86
Low-FBS astrocytes also responded to LPS+IFN-g-mediated activa-
tion by upregulating the expression of GFAP and Vim at both
mRNA and protein levels. Gfap and Vim were notably higher than
resting controls in the 48 hr post-activation, whereas at 96 hr post-
activation the expression of both IF genes had reduced back to a level
intermediate between their resting and 48 hr activated state. Protein
levels quantiﬁed from western blots performed 5 days post-activation
were likewise elevated, and increased immunoreactivity was also
evident in ﬂuorescence micrographs. This response, reminiscent of
canonical astrogliosis, was ideally suited to subsequent characteriza-
tion of siRNA-3WJ efﬁcacy.
Our basic siRNA-3WJ designs were based on the pRNA-derived 3WJ
architecture, well established as a novel and efﬁcacious RNAi delivery
platform.43 Themulti-armed nature of the systemmakes it well suited
to modular and/or multifunctional applications, with room for
expansion beyond these current proof-of-concept experiments.
Furthermore, the size of such siRNA-3WJs has previously been estab-
lished to be approximately 5–30 nm (functionality dependent),27
optimally sized to be taken up into cells without signiﬁcant loss to
renal ﬁltration or stimulation of the innate immune response. More-
over, this size is well suited to diffusion within the brain, being at the
lower end of the range estimated for the size of the extracellular
space.87 The pRNA system has demonstrated considerable promise
in the targeted delivery of RNAi or small-molecule drugs for anti-can-
cer and anti-viral applications in vitro and in vivo,26,88,89 but these
current studies represent the ﬁrst applications in a CNS-speciﬁc envi-
ronment. The present designs incorporate a single siRNA sequence
per structure, each of which were selected to match the target
sequences employed in commercially validated anti-Gfap, -Vim,
-Lcn2, and non-targeting siRNA pools. Upon reaching an intracel-
lular environment, the siRNA moiety is cleaved from the 3WJ by
the endonuclease Dicer before entering the RNA-induced silencing
complex (RISC) and guiding the cleavage of mRNA strands comple-
mentary to the target sequence.90
The two longer RNA strands of each 3WJ (A and C strands) were
prepared via in vitro transcription and dephosphorylated to remove50-triphosphate groups, an artifact of transcription using nucleotide
triphosphates. In mammalian cells, the presence of uncapped
50-triphosphate (or diphosphate) groups on nucleic acids is a known
PAMP, recognized in the cytosol by the RIG-I helicase as a probable
viral infection and triggering a type I IFN inﬂammatory response.91,92
Indeed, siRNA-3WJs retaining their 50-triphosphate groups provoked
a signiﬁcant pro-inﬂammatory response in transfected astrocytes,
evident as increased levels of Ifnb1, Il6, and Tnf. This effect was
mirrored by signiﬁcant increases in the quantity of secreted IL-6
and TNF-a upon transfection with phosphorylated siRNA-3WJs.
No such induction, neither at the mRNA nor protein levels, was
evident upon transfection with the dephosphorylated constructs,
which bypass the RIG-I-mediated antiviral response.93 An avoidance
of RIG-I-mediated IFN responses is an important consideration for
nucleic acid nanotherapeutics94 and particularly pertinent in this
context because the activation of RIG-like receptor signaling has
been directly implicated in the onset of astrogliosis.95 The dephos-
phorylated transcripts were subsequently annealed together with a
third, synthetic B strand to yield the assembled construct.
Moreover, 3WJ transfection was found to have no off-target effect on
the expression of putative reference genes in qPCR experiments, an
important validation for experiments utilizing the 2DDCt method
of assaying relative gene expression.96 Our reference gene of choice,
Gapdh, was unaffected by activation or transfection, with or without
a 3WJ payload. 3WJs were found to be non-toxic, with doses as high
as 50 nM showing negligible impact on the viability of astrocytes for at
least 120 hr post-transfection.
Thus, these preliminary assessments speak to the safety of the 3WJ
therapeutic platform in a CNS context; however, more extensive
proﬁling, especially pertaining to potential off-target effects,97 would
be required before any translational push.
Upon transfection, the siRNA-3WJs were successfully able to knock
down the expression of their target genes in a speciﬁc and dose-
dependent manner. Preliminary studies pointed toward an optimal
dose of 5 nM as the basis for further investigation; higher doses
yielded no appreciable increase in silencing efﬁcacy, possibly because
of saturation of the RNAi machinery.98 At this dose, the G10- and
V10-3WJs induced >60% knockdown of their respective target genes
relative to non-transfected controls. The extent of downregulation
was similar under resting conditions and two different activation pro-
ﬁles: preventative and therapeutic. The preventative approach is in-
tended to forestall the onset of activation, whereas the therapeutic
method is perhaps the more clinically relevant scenario as it seeks
to ameliorate already present astrogliosis. Combinatorial approaches
employing both G10- and V10-3WJ did not reveal any synergistic,
antagonistic, or compensatory effects, and neither anti-IF 3WJ had
a signiﬁcant effect on the expression of the other IF, at least at the
mRNA level, despite the interfunctionality of these two IFs.99 Alterna-
tively, treatment with LGV1-3WJ, targeting all three mRNAs, signif-
icantly downregulated each gene simultaneously, demonstrating the
potential for multifunctionality and adaptability in the 3WJ platform.Molecular Therapy: Nucleic Acids Vol. 10 March 2018 113
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effect on Gfap or Vim levels, ruling out any obvious side effects of lip-
ofection, at least with regard to IF expression. L12-3WJ was found to
nearly completely ablate the expression of Lcn2 in resting astrocytes,
again with no obvious effect on the other target genes, but was also
highly efﬁcient in activated astrocytes wherein Lcn2 expression is
many orders of magnitude higher. Such results are promising given
the relatively low concentration of the siRNA-3WJs employed
compared with other studies15 and the aim of causing a reduction
in IF expression, rather than complete silencing.
Silencing observed at the mRNA level was reﬂected at the protein
level. Strong reductions in GFAP and Vim expression were evident
in astrocytes under all resting and activation conditions. Substantial
Lcn2 knockdown was also observed. Thus, low doses of siRNA-
3WJs are capable of downregulating astrogliosis-associated molecular
markers at both mRNA and protein levels in astrocytes. However, the
broader ramiﬁcations of such an intervention require further study.
Toward this end, we also examined the effect of 3WJ treatments
on the expression of several pro-inﬂammatory cytokines and
markers. Il6 and Nos2 expression levels, each found to be elevated
in LPS+IFN-g-treated low-FBS astrocytes, were unaffected by the
substantial reductions in Gfap, Vim, or Lcn2 afforded by our
siRNA-3WJs. This may be because of the noise inherent in qPCR
quantiﬁcation of these low-abundance (high-threshold cycle [Ct])
transcripts masking change, or incongruities between the kinetics
of protein knockdown versus subsequent secondary effects on cyto-
kine/chemokine mRNA expression, and the time point at which
these are assayed. However, an effect on the expression of these
signaling mediators is not necessarily a certainty following the
knockdown of our selected targets, particularly the IFs. IL-6 and
nitric oxide (NO) synthesis play roles upstream of the induction
of IFs,81,100 so downregulation of GFAP/Vim is likely to be too
late an intervention in the astrogliosis response to modulate the
pro-inﬂammatory polarization of astrocytes. Lcn2, however, is
known to be a secreted autocrine/paracrine mediator of astrogliosis,
induced via activation of signaling pathways such as STAT3 or
NF-kB, but also able to activate those same pathways upon secretion
and subsequent binding to the 24p3R receptor on astrocytes.13,59,101
Despite this causal relationship between Lcn2 induction and astro-
cyte reactivity,64 our studies revealed no obvious consequence to
Lcn2 ablation with respect to changes in cytokine (or Nos2) or IF
expression, by qRT-PCR, western blot, immunoﬂuorescence, or
ELISA, in direct knockdown experiments. Again, this might be a
question of induction/knockdown kinetics with induction of reac-
tivity via stimulation with a large LPS+IFNg dose potentially being
sufﬁciently overwhelming to mask or inhibit therapeutic actions
resulting from siRNA-3WJ treatment.
As a means to further investigate this hypothesis, we sought to inves-
tigate the paracrine mediation of reactivity in resting astrocytes
by reactive astrocytes, ostensibly via secreted Lcn2 (among other
actors). This was accomplished by transferring media conditioned114 Molecular Therapy: Nucleic Acids Vol. 10 March 2018by activated astrocytes to non-reactive astrocytes and characterizing
the extent of the induced secondary reactivity. ACM obtained from
LPS+IFN-g-stimulated astrocytes (aACM) was found to induce a sig-
niﬁcant induction in Lcn2 and Nos2 expression in recipient resting
astrocytes. These genes are signiﬁcant in Lcn2-mediated reactivity
because Lcn2 is known to upregulate NO production, which in turn
leads to astrogliosis-associated GFAP overexpression.59,81 Moreover,
this apparent induced reactivity was completely inhibited by treating
the conditioning (stimulated) cells with L12-3WJ, with the mRNA
levels of Lcn2 and Nos2 in the aACM-treated astrocytes found to be
reduced to controls. ELISA measurements performed on the condi-
tioned media of reactive astrocytes conﬁrmed that they do signiﬁ-
cantly upregulate the secretion of pro-inﬂammatory Lcn2 upon
activation, and that this secretion is ameliorated by treatment with
L12-3WJ. The levels of secreted Lcn2 correlate well with the subse-
quent induction of Lcn2 and Nos2 expression in recipient astrocytes.
These data support the hypothesis that Lcn2, as secreted by reactive
astrocytes, can act as a signiﬁcant contributor to the propagation of
inﬂammation and astrogliosis, and that a therapeutic intervention
employing anti-Lcn2 3WJs can ameliorate this response. Neverthe-
less, other secreted factors are likely to play unique or synergistic roles
in this phenomenon. It is noteworthy that ACM from bothmock- and
N03-treated astrocytes can decrease the Lcn2 mRNA induction in
recipient cells despite little effect on Lcn2 secretion from the donor
cells. Clearly other mechanisms of activation/deactivation remain to
be elucidated, and optimization of the timing of the ACM transfer
is required to better observe the activating effects of transferred
secreted Lcn2.
To investigate the efﬁcacy of L12-3WJ in vivo, we employed an exper-
imental model of moderate contusive SCI. Local delivery of a rela-
tively low dose (10 mg) of nuclease-resistant 20F-L12-3WJ to the
injury immediately after injury signiﬁcantly reduced Lcn2 expression
compared with control mice. This downregulation was evident at
both mRNA and protein levels. Notably, the use of a comparable
dose of 20F-N03-3WJ as a negative control did not induce any signif-
icant non-speciﬁc effects in Lcn2 expression, nor did lipofectamine
injection only.
In summary, our data prove that the basic siRNA-3WJ construct is a
potent, non-toxic, and non-immunogenic platform by which to
deliver RNAi-based therapeutics in the CNS niche. Speciﬁcally, we
have demonstrated the efﬁcacious knockdown of several astroglio-
sis-associated genes, with signiﬁcant reductions in mRNA and pro-
tein expression using relatively small doses of siRNA-3WJ. Moreover,
knockdown was highly target-speciﬁc with obvious off-target
silencing negligible compared with equivalent doses of commercial
siRNA pools. Knockdown of Lcn2 resulted in a concomitant decrease
in the secretion of this neuroinﬂammatogen, thus impeding the abil-
ity of reactive astrocytes to spread inﬂammation and astrogliosis. The
silencing efﬁcacy of the platform was mirrored in preliminary in vivo
experiments, with a signiﬁcant mitigation of the early Lcn2 peak
observed in contusion SCI. Although these preliminary studies
utilized very basic siRNA-3WJ constructs, the multifunctional and
www.moleculartherapy.orgmodular nature of the platform lends itself to future optimization for
more speciﬁc in vivo applications in the CNS by incorporating further
therapeutic or targeting moieties.
MATERIALS AND METHODS
Materials
Oligonucleotides (desalted) were obtained from either Invitrogen or
Sigma, whereas siRNAs (mouse anti-Gfap, anti-Vim, and anti-Lcn2
ON-TARGETplus SMARTpools, and the ON-TARGETplus Non-
Targeting pool) were obtained from Thermo Scientiﬁc. All RNA
solutions and buffers were prepared in RNase-free water.
Cell Culture
NSCs to be differentiated into astrocytes were isolated from the sub-
ventricular zone of adult C57BL/6 mice as previously described.102
NSCs were cultured as neurospheres in NeuroCult basal medium
(mouse; STEMCELL Technologies) containing 10% NeuroCult pro-
liferation supplement (mouse; STEMCELL Technologies), 2 mg/mL
heparin (STEMCELL Technologies), 20 ng/mL recombinant human
EGF (PeproTech), 10 ng/mL recombinant human FGF-basic
(FGF2; PeproTech), and 100 U/mL penicillin-streptomycin
(GIBCO), and passaged every 3–5 days.103 High-FBS/FGF2-free
astrocyte differentiation was performed in media prepared using
low-glucose DMEM (1 g/L glucose; GIBCO) with 10% FBS (GIBCO),
1 mM glutamine, and 100 U/mL penicillin-streptomycin. Low-
FBS/+FGF2-cultured astrocytes were grown in high-FBS medium
supplemented with 50 ng/mL FGF2 for the ﬁrst 7 days before switch-
ing to a low-FBS version (1% FBS) supplemented with N-2 Supple-
ment (1 ﬁnal concentration; Life Technologies) and 50 ng/mL
FGF2. “Activation” versions of each media were also prepared, each
containing 2 mg/mL LPS (Sigma-Aldrich) and 3 ng/mL murine
IFN-g (PeproTech). All proliferating cell lines were routinely checked
for Mycoplasma contamination. NSC neurospheres were enzymati-
cally dissociated into single cells using Accumax (Sigma-Aldrich)
and plated on poly-D-lysine (PDL)-coated plastic plates or glass cov-
erslips at 80,000 cells/cm2 prior to differentiation in astrocyte media,
yielding approximately 70%–90% astrocyte conﬂuency at the later
time of analysis (FGF2-free media yielding lower conﬂuences). All
cells were cultured at 37C in a humidiﬁed atmosphere of 5% CO2.
Immunofluorescence and Confocal Microscopy
Cells grown on PDL-coated glass coverslips were ﬁxed in 4% parafor-
maldehyde for 10 min at room temperature at the appropriate time
point post-differentiation or post-transfection, following 1 hr
of serum deprivation. The coverslips were washed three times with
1 PBS before being incubated in blocking solution (1 PBS contain-
ing 0.1% Triton X-100 and 5% normal goat serum [NGS; Sigma]) for
60 min at room temperature. Fixed cells were subsequently incubated
in the same blocking solution containing the desired primary anti-
bodies (Table S2) overnight at 4C. The following day, the cells
were washed in PBS and incubated in blocking solution containing
the appropriate ﬂuorochrome-conjugated secondary antibodies
(1:1,000 dilution) for 60 minutes at room temperature. Coverslips
were subsequently washed again with PBS before cell nuclei werecounterstained with a 1 mg/mL solution of DAPI (Roche) in PBS.
After a ﬁnal wash, coverslips were mounted onto slides with ﬂuores-
cent mounting medium (Dako). Immunoﬂuorescence images were
acquired at 20 and 40 magniﬁcation using a Leica DM6000 epi-
ﬂuorescent microscope, whereas confocal images were acquired
on a Leica TCS SP5 Microscope. Images were processed using the
Fiji software package,104 and three-dimensional (3D) reconstructions
generated using Volocity (PerkinElmer).
ELISA
Levels of secreted murine IL-6, TNF-a, and Lcn2 were quantiﬁed us-
ing sandwich ELISA development kits (IL-6 and TNF-a [PeproTech],
Lcn2 [R&D Systems]). 2  106 NSCs were seeded in 10 mL of astro-
cyte medium on PDL-coated T25 plates. Medium was refreshed every
3 days, for which 3 mL was used for the assay. At 15 DIV, cells were
exposed to the activation medium. Before activation, medium was
collected (i.e., 0 hr activation). Medium was collected at 6, 12, 24,
and 48 hr post-activation. Collected medium was spun for 15 minutes
at 2,000  g at 4C, and supernatant was collected and stored
at80C. To quantify IL-6, TNF-a, and Lcn2, we used 96-well micro-
plates (Nunc-Thermo Scientiﬁc) to run the experiments. Eight-point
standard curves were generated by using serial dilutions of standard
solutions of each protein, diluted with either the diluent or the astro-
cyte medium used to differentiate NSCs into astrocytes. This has been
performed to check whether the medium can interfere in the detec-
tion of the cytokines of interest. Data analysis was performed by inter-
polating unknown concentrations with the recombinant mouse IL-6,
TNF-a, or Lcn2 standard curves after nonlinear regression ﬁt, using
the sigmoidal dose-response variable slope curve on log-transformed
data (four-parameter logistic regression).
qRT-PCR
Total RNA was extracted from cells using TRI Reagent (Sigma) and
the protocol provided by the supplier. RNA was quantiﬁed using a
NanoDrop 2000 spectrophotometer (Thermo), with purity assessed
by means of A260/A280 and A260/A230 ratios. From 500 ng of total
RNA, cDNA was generated using a High-Capacity cDNA Reverse
Transcription kit (Life Technologies) using random hexamer
primers. qRT-PCR was subsequently performed using TaqMan re-
agents (TaqMan Fast Universal PCR Master Mix [2] and FAM-
labeled TaqMan Gene Expression Assays) (Table S3) and an Applied
Biosystems 7500 Fast real-time PCR system. Where possible, exon-
spanning TaqMan probes were used to control for possible genomic
DNA contamination. Unless otherwise noted, mouse Gapdh (VIC-
labeled; Life Technologies) was used as a housekeeping reference
gene for determining relative gene expression using the 2DDCt
method.105 Each biological sample was measured in triplicate.
Western Blots
Cells were collected from six-well plates at appropriate time points
post-transfection (refer to text). Proteins were extracted from the
pellets by solubilization in radioimmunoprecipitation assay (RIPA)
buffer (Abcam) with the addition of Complete Protease Inhibitor
Cocktail (Roche) and Halt Phosphatase Inhibitor Cocktail (ThermoMolecular Therapy: Nucleic Acids Vol. 10 March 2018 115
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to inhibit serine proteases. Protein quantiﬁcation was performed us-
ing a Pierce BCA Protein Assay kit (Thermo Scientiﬁc).
Sample volumes equivalent to 20 mg of total protein were mixed with
NuPAGE LDS Sample Buffer (Life Technologies), NuPAGE Sample
Reducing Agent (Life Technologies), and distilled water prior to being
heated at 95C for 5 min. Proteins were separated by SDS-PAGE in a
10% gel using a Novex Bolt Mini Gel system and running buffer
(Tris 25 mM, glycine 192 mM, SDS 10%) before being transferred
onto Immobilon-P polyvinylidene ﬂuoride membranes (0.45-mm
pore size, methanol equilibrated; Millipore) in transfer buffer
(Tris 25 mM, glycine 192 mM, methanol 20%) for 1 hr 45 min at
4 using a Novex Bolt Mini Blot Module. A SeeBlue Plus2 standard
(Life Technologies) was used to estimate protein sizes, and transfer
was conﬁrmed by Ponceau S (Sigma) staining. For immunoblot anal-
ysis, membranes were blocked 1 hr at room temperature with 0.1%
Tween 20 and 5% dried skimmed milk powder (Marvel) in PBS
(pH 7.4) and then incubated with primary antibodies overnight at
4C (Table S4) diluted in antibody solution (0.1% Tween 20, 5% dried
skimmed milk powder in PBS) to the appropriate concentration. Af-
ter washing with PBS/0.1% Tween 20, the membranes were incubated
with the species-appropriate horseradish peroxidase-conjugated sec-
ondary antibodies (Thermo Scientiﬁc) for 1 hr at room temperature at
a 1:10,000 dilution in antibody solution. Immunoreactivity was re-
vealed using Western Lightning Plus-ECL (PerkinElmer) and imaged
using a Bio-Rad ChemiDoc XRS+ system with Image Lab 5.1 software
(Bio-Rad). Densitometry measurements were performed using Fiji,
with each protein band being normalized to the b-actin loading
controls.
3WJ Design and Construction
pRNA-based siRNA-3WJs were designed as per the schematic illus-
trated in Figure 3A, with an siRNA sequence of interest appended
to one of the arms of the pRNA 3WJ core as previously established.43
The siRNA sequences employed in the 3WJs described herein were
adapted from those used in the commercially obtained anti-Gfap,
anti-Vim, anti-Lcn2, and non-targeting siRNA pools used as
positive/negative controls in these experiments (Table S1). Strands
A and C of the 3WJ were designed to contain the sense and antisense
siRNA sequences, respectively.
Assembly of the siRNA-3WJs was performed according to previously
reported techniques.106 The shorter, 20-nt B RNA strand is common
to each of the 3WJ structures and so was purchased from a commer-
cial vendor as an oligonucleotide stock. The longer, approximately
41-nt A and C RNA strands of each 3WJ were obtained as double-
stranded DNA (dsDNA) templates from which the appropriate
RNA strands could be prepared by in vitro transcription. The DNA
templates were purchased as single, complementary strands, made
up as stock solutions of approximately 100 mM per strand in tris/
EDTA (TE) buffer, and equimolar amounts of each strand annealed
together in 1 tris/magnesium/saline (TMS) buffer using a thermal
cycler (5 min at 80C before cooling by 1C every 30 s until reaching116 Molecular Therapy: Nucleic Acids Vol. 10 March 2018a minimum of 4C). Each dsDNA template was designed with a 50 T7
RNA polymerase promoter sequence (TAA TAC GAC TCA CTA
TTG G) to facilitate efﬁcient transcription. Template concentrations
were quantiﬁed using a NanoDrop spectrophotometer.
Transcription of the A and C RNA strands was performed using a
TranscriptAid T7 High Yield Transcription Kit (Thermo Scientiﬁc)
using the accompanying protocol. RNA products were isolated and
puriﬁed by DNase treatment and subsequent denaturing polyacryl-
amide gel electrophoresis (10% polyacrylamide (w/v) gel with 8 M
urea in tris/borate/EDTA [TBE] buffer). RNA bands of the appro-
priate length were identiﬁed by UV shadowing, cut from the gel,
and diced into small pieces that were transferred to 1.5-mL Eppendorf
tubes. The pieces were submerged in an elution buffer (0.5 M ammo-
nium acetate, 0.1 mM EDTA, 0.1% SDS) and heated to 37C water
bath for 2 hr. The eluate was subsequently transferred to new tubes
and stored on ice while the gel pieces were subjected to a further
hour of elution using a fresh aliquot of elution buffer. All fractions
of each eluate were then combined into the same tube, and the eluted
RNA precipitated by the addition of 1/10 equivalent volumes of 3 M
sodium acetate (pH 5.2) and 2.5 equivalent volumes of 100% ethanol.
The solutions were mixed well and stored at20C overnight prior to
centrifugation (16,500  g for 30 min at 4C), removal of the super-
natant, and washing of the pellet in 500 mL of cold 75% ethanol with a
further centrifugation (16,500  g for 15 min at 4C). The superna-
tant was again discarded and the pellet brieﬂy dried in a vacuum
concentrator prior to storage at 20C until ready for siRNA-3WJ
assembly.
Before assembly, the A and C transcribed RNA strands and the B
strand oligonucleotides were re-dissolved in RNase-free water, and
the concentration of each solution quantiﬁed using a NanoDrop.
Where desired, RNA strands were labeled with a ﬂuorophore (i.e.,
Cy3) using a Label IT Nucleic Acid Labeling Kit (Mirus BioScience)
according to the supplier’s protocol with subsequent ethanol precip-
itation, re-dissolution, and re-quantiﬁcation. Transcription and label-
ing success was assayed using an additional PAGE gel, running
approximately 200 ng of each RNA strand in lanes alongside an Ultra
Low Range dsDNA ladder (Thermo Scientiﬁc) by which to ensure
each RNA strand was pure and of the correct length. Fluorescently
labeled bands were identiﬁed using a ChemiDoc XRS+ system with
the appropriate excitation wavelength, whereas non-labeled bands
were identiﬁed by UV transillumination following staining with
ethidium bromide or GelRed.
Assembly of each 3WJ was achieved by combining equimolar
amounts of the appropriate strands A and C with strand B in 1
TMS buffer, typically on a 50-mL scale in a 200-mL PCR tube. The so-
lutions were then subjected to an annealing temperature proﬁle in a
thermal cycler: heated to 80C and held for 5 min before cooling
1C every 30 s until reaching a minimum temperature of 4C. Assem-
bled 3WJs were puriﬁed of excess single RNA strands or misas-
sembled by-products using native PAGE (10% polyacrylamide in
TBM buffer, run at 4C to inhibit thermal denaturation). The 3WJ
www.moleculartherapy.orgbands are identiﬁed using UV shadowing cut from the gel and eluted
as per the single-strand transcription products, albeit with a non-
denaturing elution buffer (0.5 M ammonium acetate, 10 mM
MgCl2). The assembled 3WJs were ethanol precipitated from the
collected eluate, re-dissolved in RNase-free water, and quantiﬁed us-
ing a NanoDrop. Success of assembly was assayed by running 100 ng
of each 3WJ in an additional non-denaturing polyacrylamide or
agarose gel alongside the Ultra Low Range DNA Ladder, as well as
samples of single A, B, and C strands and annealed two-strand con-
structs. Correctly assembled 3WJs showed lower gel mobility than
did double- or single-stranded RNAs (see Figure 3B) and were diluted
to a stock concentration of 5 mM in 1 TMS buffer solution for sub-
sequent use. Further size characterization was undertaken using dy-
namic light scattering: 1 mM solutions of the 3WJs in 1 TMS were
measured using a Zetasizer Nano ZS (Malvern Instruments).
A triple-siRNA functionalized version of the 3WJ, LGV1-3WJ, was
similarly prepared from three in vitro-transcribed RNA strands,
such that each arm possessed an siRNA moiety corresponding to
the L12-, G10-, and V10-3WJs (Figure S3A). Assembly was likewise
monitored electrophoretically (Figure S3B).
Whereas 3WJs intended for in vitro use were constructed from un-
modiﬁed RNA, those made for in vivo use were assembled from
RNA strands incorporating 20-ﬂuoro modiﬁed pyrimidines to afford
greater nuclease resistance. Appropriately modiﬁed A, B, and C
strands were prepared from DNA templates via in vitro transcription
using a mutant polymerase (Durascribe T7 transcription kit;
Epicenter) and further processed as per the unmodiﬁed analogs.
In Vitro Transfection of NSC-Derived Astrocytes with siRNA/
siRNA-3WJs
Cellular delivery of RNAs was accomplished via transfection using
the liposomal transfection agent Lipofectamine RNAiMAX (Life
Technologies). Silencing experiments under resting conditions were
performed on astrocytes after 15 days differentiation in vitro using
siRNA or siRNA-3WJ concentrations of 5, 0.5, and 0.05 nM (prelim-
inary tests using primary astrocytes indicated that an optimal trade-
off between silencing and off-target effects might exist in this range;
data not shown). Immediately prior to transfection the astrocyte dif-
ferentiation medium was replaced with low-glucose (1 g/L) DMEM
serum-free medium per well. Transfections were performed accord-
ing to the protocol accompanying the Lipofectamine agent. In brief,
5 mM stock solutions of the siRNAs or siRNA-3WJ of interest were
diluted in DMEM and combined with an equivalent volume of
DMEM containing Lipofectamine RNAiMAX (5 mL of Lipofectamine
per well of a six-well plate). The solution was mixed well and allowed
to incubate for 10 min before being added to cells such that the ﬁnal
concentration of siRNA/siRNA-3WJ was 5, 0.5, or 0.05 nM, as
desired, in a 3 mL ﬁnal volume of serum-free medium. Each experi-
ment included mock transfections (Lipofectamine only, no RNA) and
untreated control wells (DMEM only, no RNA or Lipofectamine).
The transfection medium in each well was replaced with FBS-con-
taining astrocyte differentiation medium 6 hours post-transfection.RNA samples were collected 48 hours post-transfection and proteins
collected at various time points post-transfection, according to previ-
ously described methods. In order to investigate the effect of the
RNAs on reactive astrocytes, we repeated the experiments (at 5 nM
siRNA concentrations only) under activation conditions. Astrocytes
were stimulated with LPS+IFN-g-containing media for 48 hours
prior to (therapeutic) or concurrent with and following (preventative)
transfection at 15 DIV, with total RNA/protein collection performed
as per the unstimulated samples.
Cytotoxicity Assay
The toxicity of siRNA-3WJ treatment was ascertained using a LDH-
Cytotoxicity Assay Kit II (Abcam), following the instructions pro-
vided. Toxicity/viability was normalized to non-transfected controls
(100% viability) and samples lysed with a 10% solution of Triton
X-100 (0% viability). Assays were performed on the supernatant of
low-FBS/+FGF2 astrocytes grown in six-well plates, at time points
of 24, 48, and 120 hr post-transfection. The 48- and 120-hr time
points included a medium change at 6 hr post-transfection.
Conditioned Medium Experiments
Conditioning astrocytes, activated with or without a concomitant
transfection with 5 nM L12-3WJ, were washed twice with PBS
and had their medium exchanged for DMEM (low glucose,
100 U/mL penicillin-streptomycin) at 24 hr post-transfection/
activation. At 48 hr post-transfection/activation this ACM was
spun at 600  g for 10 min to remove debris; some of this medium
was collected for ELISA measurements, whereas the remainder was
transferred to recipient resting astrocytes. After a further 24 hr, the
RNA of these target astrocytes was collected for qPCR analysis.
Contusion Model of SCI in Mice and siRNA-3WJ Injections
All experimental procedures were performed in accordance with the
Animals (Scientiﬁc Procedures) Act 1986 Amendment Regulations
2012 following ethical review by the University of Cambridge Animal
Welfare and Ethical Review Body (AWERB). Animal work was
covered by the PPL 700/8840 (S.P.). A total of n = 20 adult 4- to
6-week-old male C57BL/6 mice (Charles River) were deeply anesthe-
tized with 2% Isoﬂurane in oxygen (1.5 L/min), and a single-vertebra
laminectomy was performed in order to expose the spinal cord at the
T12 level. A moderate injury was performed using a 70 kdyne force
from an Inﬁnite Horizon Impactor (Precision Systems and Instru-
mentation), as previously described by Cusimano et al.107 Following
the injury, two different quantities (1 and 10 mg) of 20F-modiﬁed
L12-3WJ were delivered via transfection using the liposomal transfec-
tion agent Lipofectamine RNAiMAX (Life Technologies) into the
parenchymal lesion center using a 5-mL syringe with a short 33G
needle (Hamilton), in a total injection volume of 500 nL. Control
animals received equivalent volume injections of either 10 mg of the
negative control 20F-N03-3WJ or diluted Lipofectamine RNAiMAX
vehicle alone, or were part of an injury-only (sham) group. Ex vivo
analyses were subsequently performed on three to four mice of
each of the ﬁve treatment groups. Buprenorphine (Temgesic) was
provided pre- and post-operatively; enroﬂoxacin (Baytril; Bayer)Molecular Therapy: Nucleic Acids Vol. 10 March 2018 117
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Bladders were manually expressed twice daily.
Tissue Processing, Ex Vivo Analysis, and Tissue Pathology
2 days after injury/injections, mice were anesthetized with an intra-
peritoneal injection of ketamine 10 mg/mL (Boehringer Ingelheim)
and xylazine 1.17 mg/mL (Bayer), and transcardially perfused with
saline (sodium chloride 0.9%) plus 0.5 M EDTA (Sigma), followed
by cold 4% para-formaldehyde (PFA) in PBS (pH 7.4). The isolated
spinal cords were post-ﬁxed in the same solution for 12 hr at 4C.
Tissues were then washed with PBS and cryoprotected for at least
24 hr in 30% sucrose (Sigma) in PBS at 4C. Finally, samples were
embedded in Optimal Cutting Temperature (OCT) compound
(VWR Chemicals) and frozen using dry ice. Frozen cord blocks
were placed in a cryostat (CM1850; Leica), and 25-mm-thick axial sec-
tions were cut and collected onto SuperFrostPlus slides (Thermo
Scientiﬁc). A total of 10.5 mm of each cord segment, centered onto
the lesion site, was cut and collected onto slides. Sections were then
stored at 80C until needed.
RNA was extracted from four tissue slides. Spinal cord segments were
gently detached from the coverslips using a blade and placed into a
1.5-mL tube. Total RNA was extracted by resuspending tissues in
500 mL of TRI Reagent (Sigma) and incubating at room temperature
for 10 min. Proteinase K from Tritirachium album (Sigma) was acti-
vated at 37C for 10 min prior to addition to the TRI/RNA solutions
at a 1:100 dilution and incubated at 55C for 2 hr, followed by 80C
for 15 min. RNA was then isolated, reverse transcribed, and subjected
to qPCR as described above.
For quantiﬁcation of Lcn2+ volumes, tissue sections were pre-
treated with peroxidase 3% for 15 min and then incubated for
1 hr at room temperature in the blocking solution (PBS, 10%
NGS [Sigma-Aldrich], 0.3% Triton X-100 [Sigma]). Anti-Lcn2 pri-
mary antibody (MAB1857; R&D Systems) was diluted (1:200) in a
solution of PBS + 1% NGS ± 0.3% Triton X-100 and incubated at
4C overnight. The following day, after washing the sections with
PBS 1, the appropriate biotinylated secondary antibody was
diluted in a solution of PBS + 1% NGS, 0.3% Triton X-100 and
incubated for 1 hr at room temperature. “A” and “B” components
of a Vectastain Elite ABC kit (Vector Laboratories) were then incu-
bated for 1 hr at room temperature, and ﬁnally the reaction
was developed using 3,30-diaminobenzidine (DAB) following the
supplier’s instructions. The reaction was blocked by washing the
sections with distilled water, and sections were counterstained
with hematoxylin. The sections were then dehydrated with
increasing % alcohol solutions, washed in xylene (Merck), and
mounted with a synthetic Eukitt mounting medium (Sigma).
Lcn2+ areas were outlined from a total of n = 7 equally spaced axial
spinal cord sections using an Olympus BX53 microscope with motor-
ized stage andNeurolucida software (v11.07 64-bit; Microbrightﬁeld),
and descriptive 3D spinal cord reconstructions were obtained. Lesion
margins were determined by using hematoxylin staining, and data118 Molecular Therapy: Nucleic Acids Vol. 10 March 2018were expressed as the percentage (%) of Lcn2+ volumes per
section (±SD).
Statistical Methods
Statistical analyses were performed using the GraphPad Prism 6 soft-
ware package. One-way ANOVA followed by Dunnett’s multiple
comparison test was used for comparison of three or more experi-
mental groups (qRT-PCR data), whereas two-way ANOVA with
Bonferroni post-tests was used for multi-group comparisons under
multiple conditions. For comparison of two experimental groups,
Student’s t test was applied withWelch’s correction. Graphical results
are expressed as the mean ± SD and textual descriptions as the
mean ± SEM, typically derived from the means of n = 3 technical
replicates from N R 3 biological replicates. Statistical analysis was
conducted at 95% conﬁdence level. A p value less than 0.05 was
considered as statistically signiﬁcant (*p % 0.05; **p % 0.01;
***p % 0.001; or ****p % 0.0001 relative to controls). Speciﬁcs of
the statistical analyses of each experiment are detailed in the corre-
sponding ﬁgure captions.
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